CLINICAL TRIALS PROFILE FOR FOSAPREPITANT DIMEGLUMINE

All Clinical Trials for FOSAPREPITANT DIMEGLUMINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00818259 ↗	A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)	Terminated	Merck Sharp & Dohme Corp.	Phase 1	2009-02-05	This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
NCT00895245 ↗	Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy	Terminated	National Cancer Institute (NCI)	Phase 2	2009-02-01	RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation therapy.
NCT00895245 ↗	Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy	Terminated	University of Washington	Phase 2	2009-02-01	RATIONALE: Fosaprepitant dimeglumine, palonosetron hydrochloride, and dexamethasone may help lessen or prevent nausea and vomiting caused by cisplatin in patients with head and neck cancer undergoing chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well fosaprepitant dimeglumine together with palonosetron hydrochloride and dexamethasone works in preventing nausea and vomiting caused by cisplatin in patients with stage III or stage IV head and neck cancer undergoing chemotherapy and radiation therapy.
NCT00945321 ↗	A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)	Completed	Merck Sharp & Dohme Corp.	Phase 1	2009-02-01	This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.

Clinical Trial Conditions for FOSAPREPITANT DIMEGLUMINE

Condition Name

Condition Name for FOSAPREPITANT DIMEGLUMINE
Intervention	Trials
Chemotherapy-induced Nausea and Vomiting	5
Vomiting	3
Nausea	3
Sarcoma	2

Condition MeSH

Condition MeSH for FOSAPREPITANT DIMEGLUMINE
Intervention	Trials
Vomiting	15
Nausea	10
Sarcoma	2
Cytokine Release Syndrome	1

Clinical Trial Locations for FOSAPREPITANT DIMEGLUMINE

Trials by Country

Trials by Country for FOSAPREPITANT DIMEGLUMINE
Location	Trials
United States	54
Russian Federation	3
Hungary	3
Greece	2
Poland	1

Trials by US State

Trials by US State for FOSAPREPITANT DIMEGLUMINE
Location	Trials
Texas	3
California	3
Michigan	2
Oregon	2
Washington	2

Clinical Trial Progress for FOSAPREPITANT DIMEGLUMINE

Clinical Trial Phase

Clinical Trial Phase for FOSAPREPITANT DIMEGLUMINE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2	4

Clinical Trial Status

Clinical Trial Status for FOSAPREPITANT DIMEGLUMINE
Clinical Trial Phase	Trials
Completed	7
Terminated	6
Recruiting	2

Clinical Trial Sponsors for FOSAPREPITANT DIMEGLUMINE

Sponsor Name

Sponsor Name for FOSAPREPITANT DIMEGLUMINE
Sponsor	Trials
Merck Sharp & Dohme Corp.	7
National Cancer Institute (NCI)	6
M.D. Anderson Cancer Center	2

Sponsor Type

Sponsor Type for FOSAPREPITANT DIMEGLUMINE
Sponsor	Trials
Other	12
Industry	10
NIH	6